Display search results for ** instead (57 products)

Showing 1-10 of 57

18 Mar 2016  |  North America

Vital Signs - Drug Development Focus on Genetically Modified Swine

Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs

The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...

USD 450.00

USD 337.50 save 25 %

18 Mar 2016  |  North America

Vital Signs - Stem Cell Therapy in Ischemic Stroke Recovery

Additional Clinical Trials Critical to Building on Early Promise

As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only ...

USD 450.00

USD 337.50 save 25 %

04 Apr 2016  |  Global

Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016

Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes

This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.

USD 450.00

USD 337.50 save 25 %

05 Jan 2016  |  Global

Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise

This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.

USD 450.00

USD 337.50 save 25 %

12 Feb 2016  |  Global

Vital Signs - Impact of Strategic Acquisitions on Life Sciences Market, 2016

Portfolio Expansions Follow Acquisitions by Panasonic Healthcare Holdings Co.,Thermo Fisher Scientific and Abbott Laboratories

This Vital Signs issues discusses Panasonic Healthcare's completed acquisition of Bayer's Diabetes Care Unit, Thermo Fisher Scientific's acquisition of Affymetrix, several moves in the single cell-genomics market by Bio-Rad, Illumina, Qiagen, and 10x Genomics, and Abbott's acquisition of Alere.

USD 450.00

USD 337.50 save 25 %

04 Feb 2016  |  Global

Vital Signs - Spiraling US Drug Costs, Wearable Healthcare Technologies and the Zika Virus, An Analysis

Urgent Remedial Action Required as Nearly 1/4th US Prescription Drug Users Find it Difficult to Afford their Prescriptions

This issue of Vital Signs discusses why the US pays more than other countries for drugs, the inside story on wearable electronics, the spreading Zika virus, and soaring US drug costs.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.

USD 450.00

USD 337.50 save 25 %

04 Jan 2016  |  Europe

Open AI - An Analysis

For True Sharing of Gains, Open AI Needs to Freely Share Not only Software but, More Importantly, the Data Sets it Uses

Recently, Frost & Sullivan published an ICT Beats article titled The Only Thing That Matters in Machine Learning is Data. The core of this article posits that open-sourcing machine learning code has proved, beyond doubt, that the most important asset in machine learning is data.

USD 500.00

USD 375.00 save 25 %

Showing 1-10 of 57